Figure 6.

Antitumor Activity of Multiple Cycles of TG6002/5-FC

Mean tumor volume after multiple cycles of TG6002/5-FC. Mice bearing LoVo subcutaneous xenografts were treated with one or two cycles of TG6002/5-FC. In the single cycle of treatment, at day 10 (indicated by vertical arrow), mice were treated with one intravenous administration of vehicle (open diamonds, vehicle + water; solid diamonds, vehicle + 5-FC) or with one intravenous administration of TG6002 at 1 × 10⁷ PFU (open red squares, TG6002 + water; closed red squares, TG6002 + 5-FC). Seven days after viral injection, 5-FC (200 mg/kg per day) was administered for 3 weeks (indicated by a horizontal arrow). In the multiple cycles of TG6002/5-FC treatment, at days 10 and 31 (indicated by vertical arrows), mice were treated with one intravenous administration of TG6002 at 1 × 10⁷ PFU (open green squares, TG6002 + water; closed green squares, TG6002 + 5-FC). Seven days after each viral injection, 5-FC (200 mg/kg per day) was administered for 2 weeks (indicated by horizontal arrows). The data represent the mean ± SD of 12 animals.